A case study of a patient‐centered reverse translational systems‐based approach to understand adverse event profiles in drug development-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A case study of a patient‐centered reverse translational systems‐based approach to understand adverse event profiles in drug development

Published:2022-01-11 Issue:4 Volume:15 Page:1003-1013
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Kim Sarah¹^ORCID,Lahu Gezim²,Vakilynejad Majid³,Soldatos Theodoros G.⁴,Jackson David B.⁴,Lesko Lawrence J.¹,Trame Mirjam N.¹

Affiliation:

1. Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy University of Florida Orlando Florida USA

2. thinkQ2 Baar Switzerland

3. Takeda Oncology Cambridge Massachusetts USA

4. Molecular Health GmbH Heidelberg Germany

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13219

Reference47 articles.

1. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

2. Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects

3. Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-dependent Pathways

4. Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation

5. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3);Pharmaceutics;2023-06-07

2. Application of a patient‐centered reverse translational systems‐based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors;Clinical and Translational Science;2022-03-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3